BLA 761486 · Vera Therapeutics Inc.
Trutakna
Atacicept-Vymj · Subcutaneous
NovelPriority reviewCDER novel approval, Jul 7, 2026: To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression
Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Jul 7, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
18
4 Phase 3, 1 recruiting
FAERS reports
8
8 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 5, 2026.
TRUTAKNA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether TRUTAKNA slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. TRUTAKNA is a B-lymphocyte stimulator (BLyS)-specific inhibitor and A Proliferation Inducing Ligand (APRIL) blocker indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. ( 1 ). This indication is approved under accelerated approval based on a reduction of proteinuria. It has not been established whether TRUTAKNA slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.
Mechanism: Atacicept-vymj, a BLyS-specific inhibitor and APRIL blocker, is a TACI-Fc fusion glycoprotein that binds B cell activating factor (BAFF) and APRIL with dissociation constants (Kd) of 106 pM and 33 pM, respectively, and reduces BAFF- and APRIL-mediated signaling. BAFF is also known as BlyS. Reduction in BAFF- and APRIL-mediated signaling decreases production of serum galactose deficient IgA1 (Gd-IgA1), which is implicated in the pathophysiology of IgAN.
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 7, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
- TRUTAKNA · ATACICEPT-VYMJ 150MG/ML · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Atacicept" as an intervention, any sponsor and status, largest first.
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of AtaciceptEnrolling by invitation
Vera Therapeutics, Inc.Industry
NCT06674577 · 750 participants (planned) · Start Dec 1, 2024 · Primary completion May 21, 2031
Drug: Atacicept 150 mg · For: IgA Nephropathy (IgAN); Renal and Urinary Disorders; Berger Disease
Sites: Brisbane, California
- Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)Pivotal-lookingCompleted
EMD SeronoIndustry
NCT00624338 · 461 participants · Start Jan 2008 · Primary completion Apr 2012
Drug: Atacicept 75 mg; Atacicept 150 mg · For: Lupus Erythematosus, Systemic
Sites: Birmingham, Alabama; Palo Alto, California; San Diego, California · 113 sites in all
- Atacicept in Subjects With IgA NephropathyPivotal-lookingActive, not recruiting
Vera Therapeutics, Inc.Industry
NCT04716231 · 428 participants · Start Jun 29, 2023 · Primary completion May 15, 2025
Drug: Atacicept · For: IgA Nephropathy; Berger Disease
Sites: Brisbane, California
- Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)Pivotal-lookingCompleted
EMD SeronoIndustry
NCT00595413 · 311 participants · Start Sep 2007 · Primary completion Oct 2009
Drug: Placebo matched to atacicept; Atacicept: with loading dose and 2 more · For: Rheumatoid Arthritis
Sites: Rockland, Massachusetts; Darmstadt, Germany
- Efficacy and Safety of Atacicept in Systemic Lupus ErythematosusPivotal-lookingCompleted
EMD SeronoIndustry
NCT01972568 · 306 participants · Start Dec 2013 · Primary completion Apr 2016
Drug: Atacicept 75 milligram (mg); Atacicept 150 mg and 1 more · For: Lupus Erythematosus, Systemic
Sites: Anniston, Alabama; Birmingham, Alabama; Anaheim, California · 138 sites in all
- A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)Pivotal-lookingCompleted
EMD SeronoIndustry
NCT00430495 · 256 participants · Start Dec 2006 · Primary completion Sep 2009
Drug: Atacicept; Atacicept and 2 more · For: Rheumatoid Arthritis
Sites: Rockland, Massachusetts; Canada, Canada
- A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)Pivotal-lookingTerminated
EMD SeronoIndustry
NCT00642902 · 255 participants · Start Apr 2008 · Primary completion Sep 2009
Drug: Atacicept; Atacicept and 2 more · For: Relapsing Multiple Sclerosis
Sites: Phoenix, Arizona; Atlanta, Georgia; Northbrook, Illinois · 50 sites in all
EMD SeronoIndustry
NCT02070978 · 253 participants · Start Jul 29, 2014 · Primary completion Apr 5, 2016
Drug: Atacicept 75 mg; Atacicept 150 mg and 1 more · For: Lupus Erythematosus, Systemic
Sites: Anniston, Alabama; Birmingham, Alabama; Beverly Hills, California · 84 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood immunoglobulin g decreased3
- bedridden2
- burning sensation2
- diarrhoea2
- illness2
- inflammation2
- influenza like illness2
- laboratory test abnormal2
- nausea2
- pain2
- petechiae2
- rash2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2016 | 1 |
| 2019 | 3 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.
Lafayette R, Barbour SJ, Brenner RM, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Multicenter Study
- A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
Lafayette R, Barbour S, Israni R, et al. · Kidney Int 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- Emerging immune targets for the treatment of multiple myeloma.
Sohail A, Mushtaq A, Iftikhar A, et al. · Immunotherapy 2018 · Research Support, N.I.H., Extramural, Systematic Review
- Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders.
Kaegi C, Steiner UC, Wuest B, et al. · Front Immunol 2020 · Systematic Review
- Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus.
Nestorov I, Papasouliotis O, Pena Rossi C, et al. · J Pharm Sci 2010 · Clinical Trial, Phase I, Multicenter Study
- Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis.
Nestorov I, Munafo A, Papasouliotis O, et al. · J Clin Pharmacol 2008 · Clinical Trial, Phase I, Randomized Controlled Trial
Sponsor: Vera Therapeutics Inc.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.